Tibet Pharma 西藏药业
10 significant filings since 30 May 2026: 4 on buyback, 3 on guarantee or financial assistance and 2 on dividend, and 1 other kind. The latest, on 7 Sep 2026: 西藏诺迪康药业股份有限公司2026年半年度权益分派实施公告.
自 30 May 2026 起有 10 份重大公告：buyback 4 份、guarantee or financial assistance 3 份、dividend 2 份，另有 1 类。最新一份（7 Sep 2026）：西藏诺迪康药业股份有限公司2026年半年度权益分派实施公告。
Price History 价格走势
5 sessions 个交易日, 18 Sep to 24 Sep 2026 · Live one-minute prices · High 最高 ¥37.39 · Low 最低 ¥35.85 · −0.27% on the previous close of ¥36.58The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 西南证券 | 杜向阳 | Unrated | 18 Aug 2026 | 2 | — |
| 华鑫证券 | 胡博新,吴景欢 | Buy 买入 | 12 Apr 2026 | 1 | — |
| 信达证券 | 唐爱金,贺鑫 | Unrated | 14 Mar 2026 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 4 reports. 每行为该券商近十二个月的最新研报；4 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。